Objective To observe the efficacy of Right-Supporting Liver-Emolliating Formula for liver fibrosis in chronic hepatitis B. Methods Sixty patients were randomized into the treatment group and control group

with 30in each. The patients in both groups were orally taken Lamivudine Tablets（100mg /each time

once daily）. The treatment group was added with Right-Supporting Liver-Emolliating Formula one dose daily. The control group was added with Dahuang Zhechong Capsules（1. 6 g /each time

twice daily）. One treatment course lasted for 8 weeks and the treatment lasted for 6 courses. The TCM syndrome scores

alanine aminotransferase（ALT）

aspartate aminotransferase（AST）

total bilirubin（TBil）

albumin（ALB）

hyaluronic acid（ HA）

IV-collagen（ IV-C）

procollagen-Ⅲ（PC-Ⅲ）

laminin（LN）

AST to platelet ratio index（APRI） and ALT/AST/platelet ratio index（TPRI） were observed before and after treatment. The portal vein diameter

splenic vein diameter and thickness of spleen were detected by color Doppler ultrasound. Results The total effective rate of the treatment group and control group was93. 33% and 70. 00% respectively

with a significant difference between groups（ P < 0. 05）. The TCM syndrome scores

indicators of color Doppler ultrasound（except the control group）

liver function（except ALB in the control group） and markers of liver fibrosis in both groups were significantly decreased after treatment（ P < 0. 05 or P <0. 01）

especially in the treatment group（ P < 0. 05 or P < 0. 01）. Conclusion Right-Supporting LiverEmolliating Formula is effective for liver fibrosis in chronic hepatitis B and can improve symptoms and reduce liver injury.